Glimepiride/voglibose hypoglycemic oral preparation composition and preparation method thereof

Abstract

The present invention discloses a glimepiride / voglibose hypoglycemic oral preparation composition and a preparation method thereof, and the glimepiride / voglibose hypoglycemic oral preparation composition comprises the following raw materials: glimepiride and voglibose, a filler, a disintegrant, a binder and a lubricant, the glimepiride and the voglibose are main components, and the filler, the disintegrant, the binder and the lubricant are auxiliary materials. The glimepiride / voglibose hypoglycemic oral preparation composition is prepared by sorting, mixing granulation, drying and finished product packaging. The glimepiride / voglibose hypoglycemic oral preparation composition has the advantages of complementary main medicine action mechanism, multi targets, good patient compliance, and the like, and is more applicable to type 2 diabetes patients of which blood-glucose rises after meals and fasting blood-glucose rises insignificantly.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and in particular relates to a glimepiride / voglibose hypoglycemic oral preparation composition and a preparation method thereof. Background technique [0002] Type 2 diabetes, formerly known as adult-onset diabetes, usually occurs after the age of 35 to 40, accounting for more than 90% of diabetic patients. The ability to produce insulin in the body of patients with type 2 diabetes is not completely lost, and some patients even produce too much insulin in the body, but the effect of insulin is poor, so the insulin in the body of the patient is relatively deficient, which can be stimulated by some oral drugs Insulin secretion. [0003] Glimepiride Glimepiride is a third-generation sulfonylurea antidiabetic drug, which can inhibit hepatic glucose synthesis, promote the uptake of peripheral glucose by muscle tissue and promote insulin secretion. This product is suitable for type 2 diabetic p...

AI Technical Summary

Problems solved by technology

The ability to produce insulin in the body of patients with type 2 diabetes is not completely lost. Some patients even produce too much insulin in the body, but the effect of insulin is poor. Therefore, the insulin in the body of the patient is relatively deficient. insulin secretion

[0004] At present, most of the existing products on the market have mediocre therapeutic effects, mediocre blood sugar control effects, poor control of drug release, and general patient compliance.